Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis is an autoimmune condition caused by immunoglobulin (Ig)G antibodies directed against the NR1 subunit of the NMDA glutamate receptor. Approximately 65% of cases present with psychiatric symptoms, particularly psychosis. It remains to be established whether anti-NMDA receptor antibodies can cause a ‘purely’ psychotic illness without overt neurological symptoms. Method: We conducted a systematic literature search to establish what proportion of patients with schizophrenia and related psychoses have antibodies directed against the NMDA receptor. Studies were included if (a) subjects had a diagnosis of schizophrenia, schizophrenia spectrum disorder or first-episode psychosis (FEP) using standard criteria, (b) serum was analysed for the presence of anti-NMDA receptor antibodies; and (c) the purpose of the study was to look for the presence of anti-NMDA receptor antibodies in patients with a primary psychiatric diagnosis without clinical signs of encephalitis. Results: Seven studies were included, comprising 1441 patients, of whom 115 [7.98%, 95% confidence interval (CI) 6.69–9.50] were anti-NMDA receptor antibody positive. Of these, 21 (1.46%, 95% CI 0.94–2.23) patients were positive for antibodies of the IgG subclass. Prevalence rates were greater in cases than controls only for IgG antibodies; other subclasses are of less certain aetiological relevance. There was significant heterogeneity in terms of patient characteristics and the antibody assay used. Conclusions: A minority of patients with psychosis are anti-NMDA receptor antibody positive. It remains to be established whether this subset of patients differs from antibody-negative patients in terms of underlying pathology and response to antipsychotic treatment, and whether immunomodulatory treatments are effective in alleviating psychotic symptoms in this group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488 · cited 3×
“These antibodies were later characterized as immunoglobulin (Ig)G antibodies reactive with the NMDA receptor (Dalmau et al. 2007), specifically the NR1 subunit (Dalmau et al. 2008).”
BackgroundTitulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165 · cited 5×
“Significant neurocognitive deficits are common after recovery and relapse is well recognized, occurring in 12% after 2 years (Titulaer et al. 2013).”
BackgroundInfluentialParaneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492 · cited 5×
“These antibodies were later characterized as immunoglobulin (Ig)G antibodies reactive with the NMDA receptor (Dalmau et al. 2007), specifically the NR1 subunit (Dalmau et al. 2008).”
BackgroundResultInfluentialCellular and synaptic mechanisms of anti-NMDA receptor encephalitis
Hughes, E. G., Peng, X., Gleichman, A. J., Lai, M., Zhou, L., Tsou, R., Parsons, T. D., Lynch, D. R., Dalmau, J., & Balice-Gordon, R. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0167-10.2010 · Cited by 1,143
Irani, S. R., Bera, K., Waters, P., Zuliani, L., Maxwell, S., Zandi, M. S., Friese, M. A., Galea, I., Kullmann, D. M., Beeson, D., et al. (2010) · Brain · doi:10.1093/brain/awq113 · Cited by 1,035
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035 · cited 1×
“Although the dopamine hypothesis has dominated theories of the aetiology of schizophrenia, there is an increasing recognition that dysfunction in the glutamate system is of central importance and may even be primary to the dopaminergic dysfunction (Moghaddam & Javitt, 2012).”
BackgroundThe Computational Anatomy of Psychosis
Adams, R. A., Stephan, K. E., Brown, H. R., Frith, C. D., & Friston, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00047 · Cited by 850 · cited 1×
“There now exists a significant body of work demonstrating, on a computational or informationprocessing level, how NMDA antagonism and/or hypofunction might lead to the phenomenological or clinical signs and symptoms of schizophrenia (Corlett et al. 2011; Rolls & Deco, 2011; Adams et al. 2013).”
BackgroundBenros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., & Mortensen, P. B. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030516 · Cited by 582
Neuronal autoantigens—pathogenesis, associated disorders and antibody testing
Lancaster, E., & Dalmau, J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.99 · Cited by 512
Hammer, C., Stepniak, B., Schneider, A., Papiol, S., Tantra, M., Begemann, M., Sirén, A.-L., Pardo, L. A., Sperling, S., Mohd Jofrry, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.110 · Cited by 342
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295 · cited 1×
“Furthermore, anterior cingulate glutamate following ketamine administration correlates with positive psychotic symptomatology (Stone et al. 2012).”
BackgroundKinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256 · cited 1×
“Although work is ongoing, effect sizes are often modest and some of the compounds with the greatest initial promise (such as the metabotropic glutamate receptor 2/3 agonist LY2140 023) have performed disappointingly in patient trials (Kinon et al. 2011).”
BackgroundGlutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229 · cited 3×
“Pharmacological NMDA antagonism in humans and animals can cause a state that some authors describe as catatonic (Corlett et al. 2011).”
BackgroundIgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment
Prüss, H., Höltje, M., Maier, N., Gomez, A., Buchert, R., Harms, L., Ahnert-Hilger, G., Schmitz, D., Terborg, C., Kopp, U., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318258300d · Cited by 143
Anti-inflammatory treatment in schizophrenia
Müller, N., Myint, A.-M., Krause, D., Weidinger, E., & Schwarz, M. J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.008 · Cited by 89 · cited 1×
“Small numbers of schizophrenia patients have received antiinflammatory and immunomodulatory treatments (e.g. corticosteroids, celecoxib, minocycline, plasmapharesis, azathioprine), but mainly with limited success (reviewed in Muller et al. 2013).”
BackgroundIncreased prevalence of antibrain antibodies in the sera from schizophrenic patients
Henneberg, A. E., Horter, S., & Ruffert, S. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90004-3 · Cited by 87 · cited 1×
“Reports of increased prevalence of anti-brain antibodies in the sera of patients with schizophrenia were published as early as the 1930s (Henneberg et al. 1994).”
Background
Cited by
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Leypoldt, F., Armangue, T., & Dalmau, J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12553 · Cited by 416
Pollak, T. A., Lennox, B. R., Müller, S., Benros, M. E., Prüss, H., Tebartz van Elst, L., Klein, H., Steiner, J., Frodl, T., Bogerts, B., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30290-1 · Cited by 402
Self-citationThe blood–brain barrier in psychosis
Pollak, T. A., Drndarski, S., Stone, J. M., David, A. S., McGuire, P., & Abbott, N. J. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30293-6 · Cited by 307
Self-citation
Metadata
- Authors
- Pollak, T. A., McCormack, R., Peakman, M., Nicholson, T. R., & David, A. S.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2013-12-13
- Volume
- 44
- Issue
- 12
- Pages
- 2475-2487
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2056221453
- Cited by
- 155
- References
- 16
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.